The prognostic impact of tumor size in resected stage I non-small cell lung cancer: Evidence for a two thresholds tumor diameters classification

被引:44
作者
Christian, Casali [1 ]
Erica, Storelli [1 ]
Uliano, Morandi [1 ]
机构
[1] Univ Modena & Reggio Emilia, Dept Gen Surg & Surg Specialties, Div Thorac Surg, Policlin Modena, I-41100 Modena, Italy
关键词
non-small cell lung cancer; cancer staging; tumor size; prognosis;
D O I
10.1016/j.lungcan.2006.08.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: The current TNM staging system for non-small cell lung cancer subdivides stage IA and IB according to a tumor size threshold of 3 cm. Some authors have suggested that tumor size behaves as a continuous, but the optimal diameter thresholds to be adopted remain debated. Methods: We conducted a retrospective study on 548 patients who underwent a complete surgical resection at our institute for stage IA and IB non-small cell lung cancer according to the current TNM staging system. Univariate and multiaviate analysis of overall and disease-specific survival were performed. Results: Stage 1A had an overall 5 years survival of 67% and a 5 years disease-specific survival of 85%. Stage IB had an overall 5 years of 49% and 5 years disease-specific survival of 53%. Tumors <2 cm had a significantly better survival than tumors >= 2 cm (overall survival: p = 0.007; disease-specific survival: p = 0.026), as well as tumors ranging from 2 to 5 cm in comparison with larger ones (overall survival: p=0.031; disease-specific survival: p=0.013). No significant difference was found between groups ranging from 2 to 5 cm. Turnors of 2-5 cm had 57% higher probability of death in comparison with tumors <2 cm and tumors >5 cm had a probability of death 60% higher than tumor of 2-5 cm. Age and tumor size (two thresholds diameter classification) resulted independent variables at multivariate analysis. Conclusion: the definition of T factor in the staging system of non-small cell lung cancer should consider two cutoffs according to tumor size. Two and 5 cm represent appropriate thresholds diameters that define subgroups with significant different prognosis. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:185 / 191
页数:7
相关论文
共 23 条
[1]
Survival after pathological stage IA nonsmall cell lung cancer:: Tumor size matters [J].
Birim, Ö ;
Kappetein, AP ;
Takkenberg, JJM ;
van Klaveren, RJ ;
Bogers, AJJC .
ANNALS OF THORACIC SURGERY, 2005, 79 (04) :1137-1141
[2]
Prognostic factors in non-small cell lung cancer - A decade of progress [J].
Brundage, MD ;
Davies, D ;
Mackillop, WJ .
CHEST, 2002, 122 (03) :1037-1057
[3]
Prognostic value of tumor size in non-small cell lung cancer larger than five centimeters in diameter [J].
Cangir, AK ;
Kutlay, H ;
Akal, M ;
Güngör, A ;
Özdemir, N ;
Akay, H .
LUNG CANCER, 2004, 46 (03) :325-331
[4]
T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer [J].
Carbone, E ;
Asamura, H ;
Takei, H ;
Kondo, H ;
Suzuki, K ;
Miyaoka, E ;
Tsuchiya, R ;
Motta, G .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (05) :907-912
[5]
Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease [J].
Gajra, A ;
Newman, N ;
Gamble, GP ;
Abraham, NZ ;
Kohman, LJ ;
Graziano, SL .
LUNG CANCER, 2003, 42 (01) :51-57
[6]
Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph - The Lung Screening Study of the National Cancer Institute [J].
Gohagan, J ;
Marcus, P ;
Fagerstrom, R ;
Pinsky, P ;
Kramer, B ;
Prorok, P .
CHEST, 2004, 126 (01) :114-121
[7]
Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study [J].
Goya, T ;
Asamura, H ;
Yoshimura, H ;
Kato, H ;
Shimokata, K ;
Tsuchiya, R ;
Sohara, Y ;
Miya, T ;
Miyaoka, E .
LUNG CANCER, 2005, 50 (02) :227-234
[8]
Small stage I cancers of the lung: genuineness and curability [J].
Henschke, CI ;
Wisnivesky, JP ;
Yankelevitz, DF ;
Miettinen, OS .
LUNG CANCER, 2003, 39 (03) :327-330
[9]
KAKINUMA R, 2003, P INT ASS STUD LUNG, P18
[10]
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J].
Kato, H ;
Ichinose, Y ;
Ohta, M ;
Hata, E ;
Tsubota, N ;
Tada, H ;
Watanabe, Y ;
Wada, H ;
Tsuboi, M ;
Hamajima, N ;
Ohta, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1713-1721